T1	Participants 71 132	bone metastases from tumors poorly responsive to chemotherapy
T2	Participants 603 678	patients with bone metastases from tumors poorly responsive to chemotherapy
T3	Participants 218 233	bone metastases
T4	Participants 784 1003	Sixty-six patients with poorly responsive tumors such as non-small cell lung cancer (NSCLC), bladder cancer, gastrointestinal cancers, kidney cancer, melanoma and metastatic carcinoma of unknown origin entered the study
T5	Participants 1294 1482	Of the 66 patients enrolled, 9 were observed for one month or less; 7 were followed for two months; only 50 patients were followed for more than 2 months and could be adequately evaluated.
